One hypothesis to explain this is that HRT decreases the release of LH, a known mitogen for ovarian cancer; thus, the potential growth promoting effect of HRT is offset by the reduction in LH, which is usually high in postmenopausal women or in women who have undergone bilateral oophorectomy. Here, PLOD1 is linked to ovarian cancer.